A new study reports synergistic control of carbapenem-resistant E. coli biofilms by combining lytic bacteriophages with silver-chitosan nanomaterials. The preclinical work is positioned as an alternative strategy to traditional antibiotics, particularly where biofilm-associated tolerance undermines conventional treatment. For biotech innovators in anti-infectives, the signal is practical: pairing biological lysis with nanomaterial-mediated disruption may enhance penetration, reduce regrowth, and improve outcomes in resistant infections where single-modality approaches struggle. The translational path will hinge on host-safety profiles, impact on microbiome ecology, and evidence in infection-relevant models where biofilm architecture and antibiotic exposure patterns resemble clinical settings.